Učitavanje...

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma

Brentuximab vedotin (BV) is an antibody-drug conjugate that targets CD30-positive malignancies via an anti-CD30 monoclonal antibody linked to monomethyl auristatin E, a microtubule-disrupting agent, by a protease-cleavable linker. BV has received accelerated approval from the US Food and Drug Admini...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Siddiqi, Tanya, Thomas, Sandra H, Chen, Robert
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2014
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3959807/
https://ncbi.nlm.nih.gov/pubmed/24672256
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S57700
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!